Abstract 303P
Background
Mandibulectomy typically involves rigid reconstruction using autologous bone and titanium plates. However, in cases with poor performance status or complications as well as the elderly, choosing the optimal surgical method is difficult. For such cases in our hospital, we do not perform rigid reconstruction but opt for only soft tissue reconstruction or primary suturing at the defect site. Here, we retrospectively investigated cases where primary suturing was applied and discuss the utility of the procedure.
Methods
This retrospective study targeted cases of stage T4 lower gingival carcinoma treated with segmental mandibulectomy and primary suturing at the defect site between 1992 and 2018. Survey items were operative time, blood loss volume, perioperative complications, length of hospitalization, and food intake at discharge.
Results
There were 186 cases for which segmental mandibulectomy was performed during the target period, and 13 cases for which primary suturing was also performed. Median operative time was 210 (range, 124-328) min. Median blood loss was 212 (101-867) mL. Six cases had complications during the perioperative period, but in all cases cure was achieved by conservative treatment. Median length of hospitalization was 32 (20-49) days. All cases could tolerate oral intake at discharge.
Conclusions
Segmental mandibulectomy without reconstruction may be a viable surgical option for cases where free tissue reconstruction is not possible.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
508P - Efficacy and safety of anti-PD-1 antibody SHR-1210 combined with apatinib in first-line treatment for advanced lung squamous carcinoma: A phase II study
Presenter: Jinliang Wang
Session: Poster display session
Resources:
Abstract
525P - Retrospective analysis of outcomes of cisplatin and irinotecan combination chemotherapy for unresectable thymic carcinoma
Presenter: Akito Fukuda
Session: Poster display session
Resources:
Abstract
524P - A study in recurrent small cell lung cancer patients, comparing weekly paclitaxel, irinotecan and temozolomide in second-line: A prospective study from a south Indian tertiary cancer hospital
Presenter: LALATENDU MOHARANA
Session: Poster display session
Resources:
Abstract
505P - PD-L1 expression in ALK rearranged NSCLC: All questions answered?
Presenter: Amrith B P
Session: Poster display session
Resources:
Abstract
487P - Afatinib versus gefitinib or erlotinib in first-line setting for Malaysia patients with EGFR mutant advanced lung adenocarcinoma
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract
492P - Feasibility of rebiopsy and sequential treatment of EGFR tyrosine kinase inhibitors in real world patients with EGFR mutant non-small cell lung cancer
Presenter: Heekyung Ahn
Session: Poster display session
Resources:
Abstract
513P - Phase II study of vitamin B12 and folate supplementation for patients undergoing chemotherapy with pemetrexed
Presenter: Shingo Kitagawa
Session: Poster display session
Resources:
Abstract
493P - Is exon 19 deletion different from exon 21 mutation in advanced non-small cell lung cancer: A single centre experience
Presenter: Sarita Shrivastva
Session: Poster display session
Resources:
Abstract
494P - Comparison of pattern of disease progression and prevalence of acquired T790M mutation in Malaysia patients with EGFR mutant lung adenocarcinoma upon failure of first-line afatinib, gefitinib and erlotinib
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract
517P - High BRCA1 expression is independently correlated with decreased overall survival in lung adenocarcinoma: Evidence from meta and bioinformatics analyses
Presenter: Fengzhu Guo
Session: Poster display session
Resources:
Abstract